169447-70-5

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-N-Boc-2-methylpiperazine is used as a synthetic intermediate for the preparation of pyrazolo[3,4-b]pyridine dual pharmacophores as PDE4-muscarinic antagonists. These dual pharmacophores have potential applications in the treatment of various diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and inflammatory conditions. The compound's unique structure allows for the development of more effective and selective drugs with improved pharmacological properties.

InChI:InChI=1/C10H20N2O2/c1-8-7-11-5-6-12(8)9(13)14-10(2,3)4/h8,11H,5-7H2,1-4H3/t8-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 74879-18-8 (S)-2-methylpiperazine 
• 888973-02-2 (2S)-1-piperazinecarboxylic acid, 2-methyl-4-(triphenylmethyl)-1,1-dimethylethyl ester 
• 859517-91-2 C₁₈H₂₆N₂O₄ 
• 170033-54-2 (S)-<2-<(2-Hydroxyethyl)(phenylmethyl)amino>-1-methyl-2-oxoethyl>carbamic acid 1,1-dimethylethyl ester 
• 170033-57-5 (S)-3-Methyl-1-(phenylmethyl)piperazin-2-one 
• 132871-10-4 (3S)-1-benzyl-3-methylpiperazine-2,5-dione 
• 132871-12-6 (S)-3-Methyl-1-(phenylmethyl)piperazine 
• 118375-95-4 methyl (S)-2-(2-chloroacetamido)propanoate 
• 169447-69-2 tert-Butyl (S)-2-methyl-4-(phenylmethyl)-1-piperazinecarboxylate 

Downstream Products

• 859517-92-3 4-[3-(2-chloro-pyrimidin-4-yl)-benzyl]-2-(S)-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 923565-72-4 1,1-dimethylethyl (2S)-2-methyl-4-((4-(2-(methyloxy)-2-oxoethyl)phenyl)methyl)-1-piperazinecarboxylate 
• 1181076-52-7 N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]propanediamide 
• 1181076-54-9 N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N'-[(6-fluoro-3'-{[(3S)-3-methyl-1-piperazinyl]methyl}-3-biphenylyl)methyl]butanediamide 
• 1181077-96-2 N-{[6-chloro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-N'-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}butanediamide 
• 1204535-34-1 1,1-dimethylethyl (2S)-4-{[2-bromo-5-(trifluoromethyl)phenyl]sulfonyl}-2-methyl-1-piperazinecarboxylate 
• 1244740-14-4 1,1-dimethylethyl (2S)-2-methyl-4-[(phenylamino)carbonyl]-1-piperazinecarboxylate 
• 1244740-08-6 1,1-dimethylethyl (2S)-4-{[(2,4-difluorophenyl)amino]carbonyl}-2-methyl-1-piperazinecarboxylate 
• 1244740-06-4 1,1-dimethylethyl (2S)-4-[(4-chlorophenyl)sulfonyl]-2-methyl-1-piperazinecarboxylate 
• 1244740-23-5 4-{[(3S)-3-methyl-1-piperazinyl]sulfonyl}benzonitrile 

Relevant academic research and scientific papers

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

Novel Compounds

The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES

The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Formula (I)

NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES

A heterocyclic inhibitor having the formula (I), with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role.

PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS

Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders r

A novel and facile method to synthesize (R)- and (S)-2-methylpiperazine

A concise and efficient synthesis of (R)- and (S)-2-methylpiperazine in only five steps from (D)- and (L)-alanine is described. The key step is reaction of benzylamine with a bifunctional molecule to build a six-membered ring.

Inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. The compounds of formula A are representative of the compounds of the present invention: STR1

Asymmetric Synthesis of 2,6-Methylated Piperazines

The complete series of enantiopure 2,6-methylated piperazines was synthesized utilizing two alternative reactions in the key bond-forming step.The dimethyl enantiomers, (2R,6R)- and (2S,6S)-2,6-dimethylpiperazine (1, 2), were prepared using either a diastereoselective triflate alkylation or a novel intermolecular Mitsunobu reaction to set the required stereochemistry.The monomethyl derivatives, (R)- and (S)-tert-butyl 2-methyl-1-piperazinecarboxylate (3, 4) were also synthesized employing the Mitsunobu cyclization strategy while the trimethyl compounds, (R)- and (S)-2,2,6- trimethylpiperazine (5, 6) were prepared using an enantiospecific triflate alkylation as the principal reaction.These methods represent efficient, general strategies for preparing a variety of 2,6-methylated piperazines for which the absolute stereochemistry can be readily controlled.